IDH2 and astrocytoma (excluding glioblastoma): The IDH inhibitors, ivosidenib, which targets IDH1, and vorasidenib, which targets IDH1 and IDH2, showed a favorable response in individuals with IDH1-mutant Grade IV astrocytoma; see Table 1 [27].